Humanized Antibody Oligomer Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies targeting amyloid-β oligomers in Alzheimer's disease therapy also bind to monomers, leading to central side-effects and reduced therapeutic efficacy, as they are not specific enough to oligomers alone.
Innovation Solution
A humanized antibody is developed that specifically binds to amyloid-β oligomers without recognizing monomers, utilizing a unique amino acid sequence in its heavy and light chain variable regions to achieve this specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies against Aβ oligomers are used, then they can bind to Aβ oligomers, but they also bind to Aβ monomers causing central side effects and reduced therapeutic efficacy
Solution Approach 1:
The patent applies local quality by engineering the antibody's binding interface to have differentiated recognition properties. The heavy chain variable region (SEQ ID NO: 12) and light chain variable region (SEQ ID NO: 14) are specifically designed to recognize conformational epitopes unique to Aβ oligomers while lacking affinity for monomeric Aβ. This localized modification of binding characteristics at the antigen-recognition site enables selective oligomer targeting without monomer cross-reactivity, thereby eliminating central side effects while maintaining therapeutic efficacy.
2Ease of manufacture
If mouse monoclonal antibodies are used, then they can be produced easily, but they induce HAMA responses in humans reducing therapeutic effect
Solution Approach 1:
The patent applies parameter changes by fundamentally altering the antibody's species origin parameter. Instead of using mouse monoclonal antibodies that are easy to produce but induce HAMA responses, the invention utilizes humanized antibody sequences (heavy chain SEQ ID NO: 12 and light chain SEQ ID NO: 14) that maintain manufacturability through recombinant DNA technology while eliminating immunogenicity in human patients. This parameter transformation from murine to humanized sequences resolves the contradiction between ease of production and therapeutic reliability.
3Power
If antibodies with high effector function are used, then they can eliminate target cells, but they have shorter blood half life
Solution Approach 1:
The patent applies dynamics by enabling flexible modulation of the antibody's effector function parameters. The humanized antibody design allows selection of different heavy chain constant regions (e.g., IgG1 for high ADCC/CDC activity with shorter half-life, or IgG2/IgG4 for reduced effector function with prolonged half-life). This dynamic adjustability of immunoglobulin subclass parameters enables optimization of the power-duration trade-off based on specific therapeutic requirements, allowing clinicians to balance immediate target cell elimination against sustained circulation time.
Data Source
Figure 1~2
Figure 3
AI summary
An anti-Aβ oligomer humanized antibody which does not bind to Aβ monomers and specifically binds only to Aβ oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of Aβ amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.